share_log

8-K: Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance

SEC ·  Aug 9 04:48
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.